|
Separate Courts Uphold Copaxone Patents, Giving Teva Security
Teva Pharmaceuticals won two major patent cases on its best-selling product in multiple sclerosis treatment Copaxone, warding off generic competition for a few more years.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives